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Abstract
This editorial introduces the new online, open access, peer-reviewed journal Trials. The journal
considers manuscripts on any aspect of the design, performance, and findings of randomised
controlled trials in any discipline related to health care, and also encourages the publication of
protocols. Trialists will be able to provide the necessary detail for a true and complete scientific
record. They will be able to communicate not only all outcome measures, as well as varying
analyses and interpretations, but also in-depth descriptions of what they did and honest reflections
about what they learnt.
Trials also encourages articles covering generic issues related to trials, for example focussing on the
design, conduct, analysis, interpretation, or reporting.
Introduction
'In 1963, Peter Medawar asked whether the scientific
paper was a fraud. He argued that the research article was
a "travesty... which editors themselves often insist upon"
because it gives "a totally misleading narrative of the proc-
esses of thought that go into the making of scientific dis-
coveries." A paper's fraud, Medawar insisted, lay mainly in
its form. The importance of the form in which research is
communicated, rather than its specific content, remains a
neglected area of inquiry.' [1]
The creation of this new journal, Trials, has been stimu-
lated by several parallel developments over recent years.
First, there has been increasing recognition of the impor-
tance of randomised controlled trials (RCTs) as the most
reliable source of evidence about the effects of health care
interventions. Second, a growing realisation has devel-
oped in parallel that not all RCTs are equal, and that reli-
able results come most readily from those trials that have
been conducted to the highest standards. Third, it is now
widely accepted that those high standards cannot be
assumed but have to be demonstrated by full and honest
reporting of trials. It is not acceptable for readers to have
to assume that certain procedures were adopted.
As interest in trials has increased, the importance of full
reporting has become more widely recognised. Yet despite
an increasing number of journals, paradoxically it seems
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to have become harder for authors to get adequate space
in journals, especially traditional paper-based ones, to
report fully the findings of their trials. Trial reports are
thus unable to do justice to the huge contribution of trial
staff and participants often over many years. Reviews of
published trials consistently show that key information is
frequently missing [2], although there is some evidence
that adoption of the CONSORT Statement has led to
improved reporting [3]. There is also growing evidence
that such space pressures influence the way that research-
ers choose to write up their studies, with a bias in favour
of selecting those outcomes that are statistically signifi-
cant [4,5].
Trials has evolved from the journal Current Controlled Tri-
als in Cardiovascular Medicine, and benefits from the hard
work in establishing that journal. The scope has been
broadened to cover all areas of health care and we will
encourage and facilitate innovation in the style of publi-
cations. Continuity is maintained by the inclusion of one
of the editors of the former journal (CF) in the steering
group of the new journal. The main focus of Trials will be
the publication of articles relating to the design, conduct,
or results of particular randomised trials. We will in addi-
tion publish articles relevant to trials in general. We con-
sider in turn aspects of these two main strands. The scope
of the journal is summarised in Table 1.
Publications relating to specific randomised 
trials
Trials  will consider manuscripts on any aspect of the
design, performance, and findings of randomised control-
led trials in any discipline related to health care, and will
also encourage the publication of protocols. Trialists will
be able to provide the necessary detail for a true and com-
plete scientific record. They will be able to communicate
not only all outcome measures, as well as varying analyses
and interpretations, but also in-depth descriptions of
what they did and honest reflections about what they
learnt.
An especially important role for Trials is to make trial pro-
tocols available to everyone. A published protocol estab-
lishes intellectual property, allows discussion of
methodological issues at greater length than is usually
allowable, and can be referred to for further methodolog-
ical detail when reporting the main trial results. Also, this
public record of a trial reduces the risk of non-publication
and may help to reduce the risk of inappropriate replica-
tion of trials. We will encourage authors to accompany
their protocol with a discussion of why the trial was set up
the way it was, indicating why alternatives were not
adopted.
Authors will be expected to follow the recommendations
of the CONSORT Statement [6]. Trials will give adequate
space to present results in suitable detail. After evidence
that trials reported as 'short reports' (500–600 words) had
serious reporting deficiencies [7] the Lancet stopped using
that format, but some journals continue. Indeed some
journals specifically note that trials with 'negative' find-
ings can be reported in brief, as if somehow those findings
are less important. But even full-length reports of say
2000–4000 words frequently fail to include key informa-
tion about methods and results. As Donald Mainland
observed in 1938:
"Limitation of journal space and the expense of publish-
ing numerous or elaborate tables usually prohibit full
publication of data, except where these are few in number;
Table 1: Scope of Trials
Articles about a specific randomised trial
Complete trial protocol
(An accompanying discussion of why the trial was designed the way it was is encouraged)
First report of trial findings
Expanded report of trial findings after a shorter version has appeared in another peer-reviewed, paper-based journal
Secondary analyses (e.g. health economic analyses, harms and other non-primary outcomes, sensitivity analyses)
Discussion of specific issues of the trial design
Description of particular aspects of the trial conduct, such as data collection, choice or measurement of outcomes, training of observers, data 
handling, organisational issues, etc
Lessons learned: "What we would do differently knowing what we know now"
Critical commentary on a trial report published elsewhere
Articles about randomised trials in general
Issues related to the design, conduct, analysis, interpretation, reporting or publication of randomised trials
Reviews of published articles describing randomised trials, relating to one or more of trial design, organisation, conduct, analysis, reporting, and 
interpretation
Issues relating to assessing outcomes, especially efforts to standardise outcomes in a particular medical field
Commentaries
Commentary to accompany articles published in Trials (usually commissioned)
Discussion of issues relating to randomised trials, especially topical mattersTrials 2006, 7:6 http://www.trialsjournal.com/content/7/1/6
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and yet incompleteness of evidence is not merely a failure
to satisfy a few highly critical readers. It not infrequently
makes the data that are presented of little or no value." [8]
The results of randomised trials should be reported,
regardless of what the findings were. We support the view
expressed by Austin Bradford Hill almost 50 years ago:
"A negative result may be dull but often it is no less impor-
tant than the positive; and in view of that importance it
must, surely, be established by adequate publication of
the evidence." [9]
A similar view was expressed by Iain Chalmers in 1990:
"Failure to publish an adequate account of a well-
designed clinical trial is a form of scientific misconduct
which can lead to those caring for patients to make inap-
propriate treatment decisions." [10]
And more recently the International Committee of Medi-
cal Journal Editors (2004) wrote:
"In return for the altruism and trust that make clinical
research possible, the research enterprise has an obliga-
tion to conduct research ethically and to report it hon-
estly." [11]
Compounding the problems of non-publication of some
studies, especially those with non-significant results, it is
clear that authors may report their results selectively,
emphasising those that are statistically significant [5]. Tri-
als will enable and encourage complete reporting of trial
results, so that all the collected information can be made
available. For this reason, Trials will consider for publica-
tion detailed, extended versions of reports of RCTs that
have already been published in a conventional, short
form.
Bearing in mind the dangers of over-summarising study
data, we encourage graphical displays that show results
for individual trial participants. We will also encourage
authors to make available all (or some of) the raw data
from the trials [12]. Such detailed reports, and especially
the raw data, will be of great value for subsequent system-
atic reviewers, whose efforts are regularly devalued by the
inadequate and even dishonest way in which trials are cur-
rently reported.
Trials  will thus facilitate the publication of a series of
linked publications from a single trial, beginning with the
study protocol:
"Electronic publication of a protocol could be simply the
first element in a sequence of 'threaded' electronic publi-
cations, which continues with reports of the resulting
research (published in sufficient detail to meet some of
the criticisms of less detailed reports published in print
journals), followed by deposition of the complete data
set. Not only would this approach allow alternative explo-
rations of the data, it would help to address some of the
growing concerns about research misconduct." [13]
A key element here, of course, is the availability of a
unique trial identifier associated with trial registration
[14]. Registration is a condition for publication in Trials of
any article based on a specific trial.
Trials will be a forum for discussing other aspects of spe-
cific randomised trials, as an important element in the full
publication of a trial or as an educational resource, or
both. Such information may provide insight into scien-
tific or practical problems (e.g. recruitment, choice of out-
come measures, resolution of logistic challenges, data
monitoring) and thus may have value for those planning
and conducting future trials.
In addition, we believe that there is scope for new and bet-
ter ways to report the findings of trials. Trials will develop
and refine innovative approaches to improving commu-
nication about trials, in particular to make the article's
message comprehensible to a variety of reader groups.
Here we anticipate taking advantage of the ingenuity of
authors and the fine advisory team that we have assem-
bled.
Trials will have a special section that will present com-
mentaries on, and critiques of, trial reports published in
other journals, with neither the time nor word constraints
of letters in those journals. We will invite the authors of
the original article to respond, and will indicate if they
choose not to do so.
Publications relating to randomised trials in 
general
Articles relating to trials in general are of particular value
as they may have a considerable beneficial impact on
many future trials.
Trials encourages articles covering generic issues related to
trials, for example focussing on the design, conduct, anal-
ysis, interpretation, or reporting of RCTs. We especially
encourage discussions of issues relating to assessing out-
comes, including efforts to standardise outcomes in a par-
ticular medical field. We will also consider articles relating
to broader issues, such as data monitoring, trial registra-
tion, and the ethical or philosophical underpinnings of
trials.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
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Trials welcomes reviews of published articles describing
RCTs relating to one or more of the following: trial design,
organisation, conduct, analysis, reporting, and interpreta-
tion. We will also publish the results of empirical method-
ological studies relating to trial methods and discussions
of generic methodological issues.
Comments
The medical literature is vast and it is impossible to keep
up with the deluge of new research articles. So is the
relentless increase in the number of journals a good thing?
We believe that there is a clear need for Trials. It fills a par-
ticular function that we do not believe exists at present. As
it is open access there will be no restriction on the availa-
bility of the information. With free online databases,
identification of and access to articles is no harder with
many journals than with just one, as long as those jour-
nals are freely available.
Because Trials is online-only it is not subject to the space
constraints of paper journals. This will enable us to move
away from the traditional format of journal articles. We
know that readers vary in their needs, from those who
want a rather short summary of the study to those who
wish to see absolutely everything. But even the former
group will wish to be reassured that the full information
is available (and indeed has been assessed as part of peer
review). Over time we aim to help to satisfy such varia-
tion.
Finally, Trials will provide a venue for publishing full trial
details to address the concerns expressed by Richard Fey-
nman in his Nobel Lecture in 1966:
"We have a habit in writing articles published in scientific
journals to make the work as finished as possible, to cover
up all the tracks, to not worry about the blind alleys or
describe how you had the wrong idea first, and so on. So
there isn't any place to publish, in a dignified manner,
what you actually did in order to get to do the work." [15]
We invite authors who share our perspective to do justice
to their trials and submit to Trials.
References
1. Horton R: The scientific paper: fraudulent or formative?
Abstract presented at Third International Congress on Biomedical Peer
Review and Global Communications, Prague, September 1997 .
2. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D,
Gøtzsche PC, Lang T, for the CONSORT Group : The revised
CONSORT statement for reporting randomized trials:
Explanation and elaboration.  Ann Intern Med 2001, 134:663-694.
3. Plint AC, Moher D, Schulz K, Altman DG, Morrison A: Does the
CONSORT checklist improve the quality of reports of rand-
omized controlled trials? A systematic review.  Fifth Interna-
tional Congress on Peer Review and Biomedical Publication, Chicago,
September 16–18, 2005 .
4. Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG:
Empirical evidence for selective reporting of outcomes in
randomized trials: Comparison of protocols to published
articles.  JAMA 2004, 291:2457-2465.
5. Williamson PR, Gamble C, Altman DG, Hutton JL: Outcome selec-
tion bias in meta-analysis.  Stat Meth Med Res 2005, 14:515-524.
6.  [http://www.consort-statement.org]. (accessed 4 March 2006)
7. Deeks JJ, Altman DG: Inadequate reporting of controlled trials
as short reports.  Lancet 1998, 352:1908.
8. Mainland D: The treatment of clinical and laboratory data Edinburgh:
Oliver & Boyd; 1938:p283. 
9. Hill AB: Contribution to the discussion of a paper by D J
Finney.  J Roy Stat Soc A 1959, 119:19-20.
10. Chalmers I: Underreporting research is scientific misconduct.
JAMA 1990, 263:1405-1408.
11. International Committee of Medical Journal Editors: Clinical trial
registration: A statement from the International Commit-
tee of Medical Journal Editors.  CMAJ 2004, 171:606-607.
12. Kirwan JR: Making original data from clinical studies available
for alternative analyses.  J Rheumatol 1997, 24:822-825.
13. Chalmers I, Altman DG: How can medical journals help prevent
poor medical research? Some opportunities presented by
electronic publishing.  Lancet 1999, 353:490-493.
14. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R,
Kotzin S, Laine C, Marusic A, Overbeke AJ, Schroeder TV, Sox HC,
Van Der Weyden MB: Clinical trial registration: A statement
from the International Committee of Medical Journal Edi-
tors.  JAMA 2004, 292:1363-1364.
15. Feynman R: Nobel lecture.  1965 [http://nobelprize.org/physics/lau
reates/1965/feynman-lecture.html]. (accessed 4 March 2006)